secwatch.observer — SEC 8-K summary
======================================

Issuer:     TFF Pharmaceuticals, Inc. (—)
CIK:        0001733413
Form:       8-K
Filed at:   2024-05-17T23:59:59+00:00
Accession:  0001213900-24-044746
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TFF Pharmaceuticals enters ATM equity offering agreement with H.C. Wainwright
-----------------------------------------------------------------------------

- Agreement allows sale of common stock at Company's discretion under effective S-3 registration statement.
- Agent commission set at 3% of gross proceeds; Company reimburses up to $50,000 in expenses.
- Sales may be made through at-the-market offerings, including negotiated and block transactions.
- No minimum or maximum offering amount specified; proceeds for general corporate purposes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1733413/000121390024044746/0001213900-24-044746-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1733413/000121390024044746/ea0206421-8k_tffpharma.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-044746

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer